top of page
-Photoroom.png)
מן העיתונות
Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data
HOUSTON, TX, May 13, 2025 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in...
NEXALIN
12 במאיזמן קריאה 5 דקות
Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering
HOUSTON, May 06, 2025 — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial...
NEXALIN
5 במאיזמן קריאה 3 דקות
Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock
HOUSTON, May 05, 2025 — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial...
NEXALIN
4 במאיזמן קריאה 3 דקות
Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback
Company initiates formal regulatory engagement on trial design for Alzheimer’s, dementia, and MCI indications HOUSTON, TX, May 01, 2025 —...
NEXALIN
30 באפר׳זמן קריאה 3 דקות
Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia
HOUSTON, TX, April 24, 2025 — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial...
NEXALIN
23 באפר׳זמן קריאה 3 דקות
Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management
AI-Powered Platform Now Fully Operational to Support Data Capture, Remote Monitoring, and Virtual Treatment with HALO™ HOUSTON, TX, April...
NEXALIN
22 באפר׳זמן קריאה 4 דקות
Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices
Proposed bipartisan legislation would expand Medicare reimbursement pathways for AI-enabled medical devices – a framework that supports...
NEXALIN
20 באפר׳זמן קריאה 4 דקות
Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders
Patent Approval Reinforces Nexalin’s Leadership in Non-Invasive Brain Stimulation for Addiction Treatment HOUSTON, TX, April 14, 2025 —...
NEXALIN
13 באפר׳זמן קריאה 4 דקות
Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial
HOUSTON, TX, April 02, 2025 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in...
NEXALIN
1 באפר׳זמן קריאה 3 דקות
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3
Houston, TX, March 26, 2025 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) is pleased to...
NEXALIN
26 במרץזמן קריאה 2 דקות
Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders
Patent Strengthens Nexalin’s Intellectual Property Portfolio and Highlights the Potential of DIFS™ Technology in Addressing Substance Use...
NEXALIN
3 במרץזמן קריאה 3 דקות
Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval
HALO™ Clarity Devices Successfully Shipped for First Phase of Clinical Trials HOUSTON, TX, Feb. 28, 2025 (GLOBE NEWSWIRE) — Nexalin...
NEXALIN
28 בפבר׳זמן קריאה 3 דקות
Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board
HOUSTON, TX, Feb. 26, 2025 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in...
NEXALIN
26 בפבר׳זמן קריאה 3 דקות
NEXALIN
19 בפבר׳זמן קריאה 0 דקות
Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition
HOUSTON, TEXAS, Feb. 10, 2025 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in...
NEXALIN
10 בפבר׳זמן קריאה 2 דקות
Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study
HOUSTON, TX, Feb. 03, 2025 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in...
NEXALIN
3 בפבר׳זמן קריאה 4 דקות
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23
HOUSTON, TX, Jan. 23, 2025 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to...
NEXALIN
23 בינו׳זמן קריאה 2 דקות
Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025
DIFS Technology: A Potential Game-Changer for Mental Health Treatments Setting New Benchmarks: 65% Response Rate Shown in Completed...
NEXALIN
14 בינו׳זמן קריאה 5 דקות
Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic
AI Components for Electronic Data Capture and Patient Monitoring to be Integrated into Phase 2 HOUSTON, TX, Dec. 23, 2024 (GLOBE...
NEXALIN
23 בדצמ׳ 2024זמן קריאה 4 דקות
New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
Report Highlights Nexalin’s Unique Non-Invasive Solution Addressing Deep Brain Dysfunction, Positioned to Revolutionize Mental Health...
NEXALIN
26 בנוב׳ 2024זמן קריאה 3 דקות
bottom of page